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Abstract: T h e  a i m: Th e aim of the study is to present the initial experience with continuous fl ow left  
ventricle assist device (CF-LVAD) in pediatric patients with BSA below 1.5 m2.
M a t e r i a l  a n d  M e t h o d s: Between 2016 and 2017, CF-LVAD (the Heartware System) have been 
implanted in three pediatric patients in the Department of Pediatric Cardiac Surgery, Jagiellonian Uni-
versity, Krakow, Poland. Th e indications for initiating CF-LVAD were end-stage congestive heart failure 
due to dilated cardiomyopathy in all children. 
R e s u l t s: Implanted patients have had BSA of 1.09, 1.42, 1.2 m2, and 37, 34, 34 kg of body weight and 
the age 12, 11, 12 years, respectively. Th e time of support was 550 days in two patients and 127 in another 
one, and is ongoing. Th e main complication has been driveline infection.
C o n c l u s i o n: Th e outcomes from our single-center experience using the HeartWare CF-LVAD have 
been excellent with a low incidence of complication and no necessity to reoperation in our patients. Chil-
dren could be successfully and safely discharged home.
Key words: mechanical circulatory support, continuous fl ow left  ventricle assist device, congestive heart 
failure in children.
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Introduction
In the last decade, the mechanical circulatory support (MCS) has become a  valuable 
therapeutic option in patients with end-stage congestive heart failure (CHF). Several 
generations of devices have been developed, but they are mainly designed for adult 
population. Th e  only available solution dedicated particularly to infants and small 
children is the pulsatile system Berlin Heart. Its superiority in long-term MCS as 
compared to extracorporeal membrane oxygenation (ECMO) has been established 
[1], demonstrating at the same time many disadvantages, such as neurological 
complications, incidences of pump thrombosis, necessity of readmissions and 
important limitations of quality of life. At present, the intracorporeal continuous 
flow left  ventricle assist device (CF-LVAD) off ers excellent patient mobility and low 
complication rates in the adult population. 
Th e  use of these devices in the pediatric population is constrained mainly by 
small patient size, but few centers have reported early experiences with CF-LVAD 
devices in the pediatric population [2–5]. Th e aim of the study is to present the initial 
experience with CF-LVAD in pediatric patients with BSA below 1.5 m2. 
Method
Between 2016 and 2017, three pediatric patients were implanted CF-LVAD in the 
Department of Pediatric Cardiac Surgery, Jagiellonian University, Krakow, Poland. 
Th e indications for initiating MCS were end-stage CHF due to dilated cardiomyopathy 
in all the patients. Taking into consideration the size of the devices, the Heartware 
System (HeartWare Inc, Miami Lakes, FL) was chosen for implantation. Th e  system 
has been previously described in details. Briefl y, it consists of a centrifugal pump, an 
integrated infl ow cannula, an outfl ow graft , and a  percutaneous driveline connected 
to an electronic controller. Th e  pump has the displacement volume of 50  cc and 
weighs 140  g. Th e  diameter of the pump is 49 mm, the total height of the pump is 
58 mm. Th e  infl ow part has a diameter of 20.5 mm and is 25 mm long. Th e outfl ow 
tube has a diameter of 10 mm, and the percutaneous driveline a diameter of 4.2 mm. 
All the implants were performed with cardiopulmonary bypass. A standard median 
sternotomy was performed during the surgical procedure. Th e  patient was put on 
cardiopulmonary bypass aft er sewing of the ring to the myocardium and coring of 
the ventricular wall, the infl ow cannula was inserted slightly anteriorly to the left  
ventricular apex. Th e  outfl ow graft  was anastomosed to the ascending aorta, using 
partial clamping. Th e  driveline was then tunneled under the sternum to the right 
upper abdominal quadrant and connected to the controller. Th e position of CF-LVAD 
with respect to the heart could be observed on postoperative chest X-rays of all the 
patients. All the patients were supported with CF-LVAD alone, despite the fact that all 
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had a high degree right heart dysfunction. Postoperative management is characterized 
in Table II, but in general, the management strategy was similar to that applied in 
patients with Fontan physiology, including nitric oxide application, a special technique 
of ventilation and even leaving the chest open in the early post-implantation period. 
A transesophageal and subsequently transthoracic echocardiography were used as 
a primary tool in monitoring ventricular function and optimization of pump speed 
while weaning the patient from cardiopulmonary bypass following implantation, and 
for further adjustments. 
Results
Patient demographics and preoperative characteristics are listed in Table 1. All the 
patients met the criteria for INTERMACS score 1 before CF-LVAD implantation. Of 
the three patients forming the study cohort, all were on intravenous inotropes prior 
to CF-LVAD initiation, two were on prolonged mechanical ventilation, while one 
patient was supported with veno-arterial ECMO. Two patients needed resuscitation 
procedures to be performed several times.
Table 1. Pre-implantation characteristics of CF-LVAD patients.
Characteristics Patient I Patient II Patient III
Age [years] 12 11 12
Gender M F M
Weight [kg] 37 34 34
Diagnosis Dilated CMP Dilated CMP Dilated CMP
BSA [m2] 1.09 1.42 1.20
Drainage of pleural cavity YES YES YES
LVEDD [mm] 60 44 55
Pre-op inotropes
milrinone,
dopamine,
levosimendan,
amiodarone,
adrenaline 
milrinone,
dopamine,
levosimendan,
adrenaline
milrinone,
dopamine,
levosimendan, 
adrenaline
Mechanical ventilation Yes Yes Yes 
ECMO Yes No No
LVEF [%] 20 23 18
BSA — body surface area, LVED — left  ventricular end-diastolic diameter, LVEF — left  ventricular ejection 
fraction, CMP — cardiomyopathy, ECMO — extracorporeal membrane oxygenation.
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Th e  operative results on the day of implantation of CF-LVAD are summarized 
in Table 2. All the patients remained on VAD support as the bridge to transplant. 
Patient  1 and 2 have been over 550 days on VAD support and continue to be 
supported. Th e post-operative chest X-ray images of the patients are shown in Fig. 1. 
None of the patients have developed signifi cant end-organ dysfunction, either in early 
or long-term follow up. In none of our patients have we observed symptoms of device 
malfunction. In patient I  and III, signs of depression and feeding intolerance were 
observed.
Table 2. Post implantation clinical outcomes in CF-LVAD patients.
Characteristics Patient 1 Patient 2 Patient 3
Operation time [min] 225 195 340
CPB time [min]  96 106 120
Outcome data [days] 570 550 127
Pump speed range [rpm] 2850–2900 2800–3200 2400–2600
Pump fl ow during fi rst 30 days [L] 2–4 4–5.1 3–4.2
Post-op NO Yes  Yes  Yes
Delayed chest closure  No  No  Yes
CPB — Cardiopulmonary bypass, NO — nitric oxide.
Fig. 1. Position of CF-LVAD aft er implantation in 3 children on chest X-ray.
In all the patients, only the LVAD system was implanted in spite of biventricular 
dysfunction. Th e  prolonged cardiopulmonary bypass time (Table 2) was related to 
right ventricular dysfunction and attempts to eliminate the implantation of the right 
ventricular assist device.
Postoperative anticoagulation was started with unfractionated heparin (the 
target activated partial thromboplastin time of 50 to 60 s). As the patients tolerated 
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oral nutrition, heparin was switched to warfarin. Th e  targeted INR for this cohort 
was well within the recommended range of 2–3. Th e  platelet inhibitors used in the 
patients were acetylsalicylic acid 1 to 2 mg/kg/day. All the patients and their families 
were trained prior to discharge home. All the patients received treatment after 
discharge including metildigoxin, aspirin and acenocoumarol with the dose adjusted 
according to INR. Patient II and III additionally received sildenafi l, ACE inhibitors 
and occasionally furosemide. Th e patients were advised to check INR, initially every 
2 days, then on a  weekly basis. Readmission occurred two times in patient 1 and 
one time in patient 2. Th e reason for readmissions and adverse events are presented 
in Table 3. In patient I, drive line infection (defi ned as appearance of erythema or 
purulent discharge around the exit site of the drive line) was the reason of several 
readmissions. CF-LVA-related thrombosis or signs of stroke were not present in any 
patient. Supra-ventricular arrhythmia was observed only during the post op period 
in patient II and III, but only in the course of the early post-implantation period. An 
emergency reference card displaying contact telephone numbers and an algorithm for 
emergency care was provided to all the patients. Before reintegration to school, school 
staff  members were educated by the family caregiver.
Table 3. Readmission and adverse events in CF-LVAD patients.
Adverse event Patient 1 Patient 2 Patient 3
Exit site infection 1 0 0
Sepsis 0 0 0
LVAD-related infection 0 0 0
Local non-LVAD infection Tooth 0 0
Device replacement NR NR NR
Right heart failure requiring RVAD NR NR NR
Renal dysfunction 0 0 0
Hepatic dysfunction 0 0 0
Cerebrovascular dysfunction 0 0 0
LVAD thrombosis 0 0 0
Cardiac arrhythmia 0 SVT SVT
Respiratory failure 0 0 0
Unscheduled readmissions Driveline infection Subtherapeutic INR 0
Readmission (No. of times) 2 1 0
Present — 1, Absent — 0, Not required — NR, SVT — supraventricular tachycardia.
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Discussion
In this study, we have demonstrated that children with low weight and BSA <1.5  m2 
can be successfully implanted with CF-LVAD and supported for long periods. 
Moreover, all our pediatric patients have been discharged home and attend their 
schools [6].
There is a  growing body of evidence that CF-LVAD is currently the optimal 
method of long-time MCS, even in pediatric patients. Th e  borderline body weight 
oscillates about 20 kg, when the patients can be supported, whereas the pulsatile 
systems, such as the Berlin Heart, remains the option for patients with lower body 
weight, when the volume of the employed paracorporeal pumps is adjusted to the 
body mass. 
One of the major advantages of the CF-LVAD systems is the possibility of 
discharging patients home; they can even attend schools and be active in everyday 
life. All the patients in our group are physically very active, what may even pose a risk 
of damaging the driveline. 
All our patients demonstrated end-stage CHF, with enhanced pharmacotherapy, 
being on mechanical ventilation, and in one case on ECMO as the bridge to CF-LVAD. 
It seems to be one of the reasons that the time from admission to discharge home was 
about one month. With the center gaining experience, the threshold for starting the 
MCS may be optimized, so that the patients might be implanted CF-LVAD before 
reaching the critical status, what may infl uence the post-implantation course. Some 
data suggest that ECMO should be generally viewed as increasing the risk of LVAD 
support in the majority of children. On the other hand, it is possible that ECMO, 
when used strictly for short-term resuscitative support to normalize end-organ 
function immediately prior to VAD implant, may improve LVAD candidacy in 
selected patients.
Patients with signifi cant problems with left  ventricle function have very frequently 
concomitant right ventricular dysfunction, so the decision must be reached whether 
the patient needs LVAD only or the biventricular MCS system implantation. 
Th e  biventricular system is highly demanding and is associated with poorer fi nal 
results. Th is is why the majority of centers prefer to start only LVAD and manage 
patients with RV failure on pharmacological support. Appreciating this strategy, 
we dedicated much eff ort to preventing biventricular MCS, what was the reason of 
prolonged time of cardiopulmonary bypass, which was not related to technical issues 
of CF-LVAD implantation. 
In our experience, the management strategy in the post-op period was very similar 
to that employed in patients aft er the Fontan operation, including special ventilation 
settings, nitric oxide administration, or even leaving the chest open shortly aft er 
initiation of CMS. Despite aggressive medical support of RV, a certain proportion of 
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patients will still develop RV failure requiring temporary mechanical RV support to 
restore blood fl ow to the pulmonary circulation and increase LV preload [7]. Studies 
suggest that an early planned biventricular assist device (BiVAD) is associated with 
better survival as compared to delayed implantation [8, 9]. Th erefore, performing 
a thorough preoperative risk assessment for RV failure is necessary to implant BiVAD 
or total artifi cial heart.
Currently, different options on temporary RV support are expressed [10]. 
Temporary ECMO support for RV failure aft er LVAD implantation was successfully 
performed in 29 (91%) patients. The  results achieved in this cohort showed the 
one-year survival rate of 74% [11], what is comparable to data from previous reports 
on temporary and permanent mechanical RV support with 6-month survival rates of 
50–60%. However, the number of thromboembolic events was higher in ECMO as 
compared to the true RVAD group with cannulation of pulmonary artery [12, 13].
Th e choosing of optimal MCS systems depends mainly on the size of the device, 
especially in patients with borderline body weight. Th ere is hope that miniaturization 
of the devices will eliminate the size limitations for CF-LVAD systems. Th e HeartWare 
MVAD (HeartWare International Inc.) small axial pump, about one-third the size of 
the HeartWare HVAD, has been tested in animal studies [14, 15]. Th e MVAD pump 
is capable of delivering fl ows ranging from 1 to 7 L/min. Th is provides the advantage 
of the pump being possibly used in patients of less than 20 kg (BSA <1 m2), in whom 
the use of the HeartWare HVAD has been limited by dimensions and restriction of 
fl ow to a minimum of 2 L/min. It is known that the usage of the Berlin Heart Excor 
for children with body weight below 5 kg is related to worse outcomes.
In patients with a  limited space in the pericardium, the technique of 
infradiaphragm implantation has been developed. In our patients, we were able to 
locate the device in the pericardial sac and the position could be observed in chest 
X-ray pictures. In adult patients, the MCS is thought to be “the bridge to transplant” 
or even destination therapy, especially when the heart transplantation is not possible. 
Th e longest reported time of MCS is about 6 years, what suggests that MCS cannot be 
recommended as the destination therapy in the pediatric population in terms of life 
time expectancy. On the other hand, the shortage of donors may cause the patients 
to be on waiting list for months or even years. Th e strategy when the CMS is applied 
as the bridge to recovery is possible mainly when the substrate of the underlying 
diagnosis has a reversible nature, as in the case of myocarditis.
Th e  present study includes a  total of three patients who underwent CF-LVAD 
implantation, with all of them (100%) successfully discharged home. It has 
a  signifi cant implication for psychosocial wellbeing of patients and their families. 
As the device technology continues to improve, the approach to pediatric MCS 
aims not only at supporting life, but also at improving quality of life of patients. 
D’Alessandro  et  al.  [16] refl ected on the “potential benefi ts that facilitate hospital 
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discharge, and a  rapid return to activities of daily living” when they published the 
fi rst reported use of HVAD in an adolescent as the bridge to transplant in the United 
States. Padalino et al. also reported two children discharged home on HVAD support. 
Th ey suggested that the patients and their families had a more positive psychosocial 
experience with the HVAD, and were more accepting of their condition as they had 
few constraints and limitations [17]. When a patient can be discharged home safely, 
it has an impact on the fi nancial status of the said patient and his family, as the child 
can return to school and the parents can resume work.
We report a low rate of adverse events and complications in the outpatient setting. 
Driveline infection was the most common complication present in patient 1, as is 
similarly reported in adult VAD series [18–20]. Th ere were no neurologic events 
or life-threatening incidents reported. Technical malfunction, controller failure, 
drive line disconnection, loss of power support and pump thrombosis can lead to 
life-threatening events in LVAD patients [21]; none of these adverse events were 
observed in our subjects. Product training for paramedics is essential, as they have 
the potential to signifi cantly aff ect patient outcome in crisis situations [21–23].
We recommend hotline services for outpatients on VAD so that they could be 
easily accessible to all families, care providers and necessary community personnel, as 
it is done in many adult centers [24–26].
Strategies aiming at prevention and treating perioperative right heart failure 
include optimization of LVAD speed guided by echocardiography, support with 
inotropes and/or use of selective pulmonary vasodilators, such as inhaled nitric oxide 
or sildenafi l, to reduce PVR [27–29].
Sparks and colleagues recently reported their experience with the HeartWare 
HVAD as the bridge to transplant in adolescents with end-stage heart failure. 
Th e outcomes were compared with a matched cohort of adult patients. Th e incidence 
of adverse events and survival aft er HVAD implant were very satisfactory and similar 
between the two groups [30]. Niebler et al. published a  case of successful support 
with the HeartWare HVAD in a patient with failed Fontan circulation as the bridge 
to cardiac transplantation, opening the path for a potential application of the device 
in this setting [31]. Th e published multi-institutional report showed only 42% success 
rate in bridging failing single ventricles to either recovery or transplant, using the 
Berlin Heart EXCOR VAD [32]. Th e  present single center institutional study is the 
initial experience of implantation of CF-LVAD in pediatric patients with small body 
size in Poland, and it demonstrates that discharge home, outpatient management and 
school integration is feasible and safe.
Th e  limitations of this study include its retrospective nature, a  small number of 
patients and single-center experience. 
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Conclusions
Th e  outcomes from our single-center experience using the CF-LVAD have been 
excellent with a  low incidence of complications and improved survival, free of stroke 
and no necessity to reoperation for device repair or replacement in our patients. 
Children could be successfully and safely discharged home.
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